论文部分内容阅读
目的观察干扰素联合利巴韦林治疗慢性丙型肝炎的近期疗效、不良反应。方法回顾性总结北京市平谷区医院1999年3月2008年7月完成治疗的慢性丙型肝炎患者30例(含1例复治病例)的临床资料,除外合并慢性乙型肝炎的患者,均符合1995年全国病毒性肝炎会议制定的诊断标准。用α-2b干扰素(安福隆)300万∪(1例复治病例用500万∪),肌肉注射,隔日一次,持续半年;利巴韦林300mg,每日3次。其中两例因对利巴韦林过敏单用干扰素治疗。记录治疗前、中、后血生化指标、丙肝抗体及HCV-RNA的变化;并记录毒副作用。结果30例均安全完成治疗,其中完全应答16例(53.3%),部分应答8例(26.7%),无应答6例(20.0%)。流感样症状21例(70%);白细胞、血小板下降19例(63.3%),脱发10例(33.3%),皮疹2例(6.67%)。结论干扰素联合利巴韦林治疗慢性丙肝,在HCV-RNA转阴方面效果较好,对复发病例仍有效。
Objective To observe the short-term curative effect and adverse reaction of interferon combined with ribavirin in the treatment of chronic hepatitis C Methods The clinical data of 30 patients with chronic hepatitis C who completed treatment in March 1999 and July 2008 in Pinggu District Hospital of Beijing were retrospectively reviewed. All patients except chronic hepatitis B were eligible 1995 national viral hepatitis meeting to develop diagnostic criteria. With α-2b interferon (An Fulong) 3000000 ∪ (1 cases of retreatment cases with 5000000 ∪), intramuscular injection, every other day, for six months; ribavirin 300mg, 3 times a day. Two of these patients were treated with interferon alone because of an allergy to ribavirin. Record before and after treatment, blood biochemical markers, hepatitis C antibodies and HCV-RNA changes; and record the side effects. Results All the 30 patients were safely treated. Among them, 16 patients (53.3%) responded completely, 8 patients (26.7%) responded partially and 6 patients (20.0%) did not respond. There were 21 cases (70%) of flu-like symptoms; white blood cells, thrombocytopenia in 19 cases (63.3%), hair loss in 10 cases (33.3%) and rash in 2 cases (6.67%). Conclusion Interferon combined with ribavirin in the treatment of chronic hepatitis C is better in HCV-RNA negative conversion and still effective in relapse cases.